知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

13 records (took 0.042 seconds)

    Carcino-embryonic antigen derivatives lacking the carboxyl terminal end
    1.
    发明授权
    Carcino-embryonic antigen derivatives lacking the carboxyl terminal end 失效
    缺少羧基末端的癌胚抗原衍生物

    公开(公告)号：US5672513A

    公开(公告)日：1997-09-30

    申请号：US217299

    申请日：1994-03-23

    Applicant: Alexey Terskikh ,  Andre Pelegrin ,  Jean-Pierre Mach

    Inventor： Alexey Terskikh ,  Andre Pelegrin ,  Jean-Pierre Mach

    IPC: A61K39/395 ,  C07K14/00 ,  C07K14/705 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574 ,  C07K14/47 ,  C07K14/82

    CPC classification number: C07K14/705 ,  Y10S530/828

    Abstract: The present invention provides recombinant CEA glycoproteins and methods for their production. These recombinant CEA glycoproteins s lack the C-terminal 26 amino acids which are present in natural CEA and are characterized in that they are free from cross-reactive CEA-like antigens, antigenically indistingiushable from the soluble form of CEA shed from tumor cells, and devoid of the ethanolamine which is present at the C-terminus of natural CEA, and also devoid of the additional amino acids which may be attached to the natural CEA through said ethanolamine. Said recombinant CEA glycoproteins s preferably have the amino acid sequence SEQ ID NO: 1. The CEA glycoproteins s of the invention may be used as reagents in an immunoassay for the diagnosis of neoplastic diseases. The invention also relates to a DNA encoding said recombinant CEA glycoprotein, such as the DNA having the nucleotide sequence SEQ ID NO: 2 or a functional equivalent sequence thereof. The present invention also relates to recombinant vectors comprising said DNA, which recombinant vector is capable of directing the expression of said DNA in a compatible host cell, and to transformed host cells containing such a recombinant vector. The recombinant CEA glycoprotein of the present invention, preferably integrated in a test-kit, may be used for determining the presence of tumor cells in a sample of body fluid.

    Abstract translation: 本发明提供重组CEA糖蛋白及其生产方法。 这些重组CEA糖蛋白缺乏存在于天然CEA中的C-末端26个氨基酸，其特征在于它们不具有从可溶形式从肿瘤细胞中流出的CEA抗原性不可抵抗的交叉反应性CEA-样抗原，以及 没有存在于天然CEA的C末端的乙醇胺，也没有可以通过所述乙醇胺与天然CEA连接的另外的氨基酸。 所述重组CEA糖蛋白优选具有SEQ ID NO：1的氨基酸序列。本发明的CEA糖蛋白可用作用于诊断肿瘤疾病的免疫测定中的试剂。 本发明还涉及编码所述重组CEA糖蛋白的DNA，例如具有核苷酸序列SEQ ID NO：2的DNA或其功能等同序列。 本发明还涉及包含所述DNA的重组载体，所述重组载体能够引导所述DNA在相容宿主细胞中的表达，以及含有这种重组载体的转化宿主细胞。 优选整合在试验盒中的本发明的重组CEA糖蛋白可用于测定体液样品中肿瘤细胞的存在。

    BRIEF RADIOIMMUNOTHERAPY
    2.
    发明申请
    BRIEF RADIOIMMUNOTHERAPY 审中-公开
    简介无线电自动化

    公开(公告)号：US20120308477A1

    公开(公告)日：2012-12-06

    申请号：US13068848

    申请日：2011-05-30

    Applicant: Vincent BOUDOUSQ ,  Isabelle Navarro-Teulon ,  Jean-Pierre Pouget ,  Andre Pelegrin

    Inventor： Vincent BOUDOUSQ ,  Isabelle Navarro-Teulon ,  Jean-Pierre Pouget ,  Andre Pelegrin

    IPC: A61K51/10 ,  A61N5/00 ,  A61P35/00

    CPC classification number: A61N5/1014 ,  A61K51/1048 ,  A61N2005/1021

    Abstract: The present invention relates to a method of treating a subject having a cancer in a body cavity characterized in that it comprises the steps of: administering in said body cavity of the subject radiolabeled binding molecules which bind to an antigen expressed by cancerous cells; washing the body cavity to remove unbound radiolabeled molecules. The present invention also relates to a body cavity perfusing system for carrying out said method.

    Abstract translation: 本发明涉及一种治疗体内具有癌症的受试者的方法，其特征在于其包括以下步骤：在所述体腔内施用结合癌细胞表达的抗原的放射性标记的结合分子; 清洗体腔以去除未结合的放射性标记分子。 本发明还涉及一种用于执行所述方法的体腔灌注系统。

Patent Agency Ranking